TAK-960 is an orally available, selective inhibitor of polo-like kinase 1 ( PLK1 ) , with an IC 50 of 0.8 nM. TAK-960 also shows inhibitory activities against PLK2 and PLK3 , with IC 50 s of 16.9 and 50.2 nM, respectively. TAK-960 inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts.